Best of the Week
Most Popular
1. The Trump Stock Market Trap May Be Triggered - Barry_M_Ferguson
2.Why are Central Banks Buying Gold and Dumping Dollars? - Richard_Mills
3.US China War - Thucydides Trap and gold - Richard_Mills
4.Gold Price Trend Forcast to End September 2019 - Nadeem_Walayat
5.Money Saving Kids Gardening Growing Giant Sunflowers Summer Fun - Anika_Walayat
6.US Dollar Breakdown Begins, Gold Price to Bolt Higher - Jim_Willie_CB
7.INTEL (INTC) Stock Investing to Profit From AI Machine Learning Boom - Nadeem_Walayat
8.Will Google AI Kill Us? Man vs Machine Intelligence - N_Walayat
9.US Prepares for Currency War with China - Richard_Mills
10.Gold Price Epochal Breakout Will Not Be Negated by a Correction - Clive Maund
Last 7 days
This Dividend Aristocrat Is Leading the 5G Revolution - 22nd July 19
What the World Doesn’t Need Now is Lower Interest Rates - 22nd July 19
My Biggest 'Fear' For Silver - 22nd July 19
Reasons to Buy Pre-Owned Luxury Car from a Certified Dealer - 22nd July 19
Stock Market Increasing Technical Weakness - 22nd July 19
What Could The Next Gold Rally Look Like? - 22nd July 19
Stock Markets Setting Up For A Volatility Explosion – Are You Ready? - 22nd July 19
Anatomy of an Impulse Move in Gold and Silver Precious Metals - 22nd July 19
What you Really need to Know about the Stock Market - 22nd July 19
Has Next UK Financial Crisis Just Started? Bank Accounts Being Frozen - 21st July 19
Silver to Continue Lagging Gold, Will Struggle to Overcome $17 - 21st July 19
What’s With all the Weird Weather?  - 21st July 19
Halifax Stopping Customers Withdrawing Funds Online - UK Brexit Banking Crisis Starting? - 21st July 19
US House Prices Trend Forecast 2019 to 2021 - 20th July 19
MICROSOFT Cortana, Azure AI Platform Machine Intelligence Stock Investing Video - 20th July 19
Africa Rising – Population Explosion, Geopolitical and Economic Consquences - 20th July 19
Gold Mining Stocks Q2’19 Results Analysis - 20th July 19
This Is Your Last Chance to Dump Netflix Stock - 19th July 19
Gold and US Stock Mid Term Election and Decade Cycles - 19th July 19
Precious Metals Big Picture, as Silver Gets on its Horse - 19th July 19
This Technology Everyone Laughed Off Is Quietly Changing the World - 19th July 19
Green Tech Stocks To Watch - 19th July 19
Double Top In Transportation and Metals Breakout Are Key Stock Market Topping Signals - 18th July 19
AI Machine Learning PC Custom Build Specs for £2,500 - Scan Computers 3SX - 18th July 19
The Best “Pick-and-Shovel” Play for the Online Grocery Boom - 18th July 19
Is the Stock Market Rally Floating on Thin Air? - 18th July 19
Biotech Stocks With Near Term Catalysts - 18th July 19
SPX Consolidating, GBP and CAD Could be in Focus - 18th July 19
UK House Building and Population Growth Analysis - 17th July 19
Financial Crisis Stocks Bear Market Is Scary Close - 17th July 19
Want to See What's Next for the US Economy? Try This. - 17th July 19
What to do if You Blow the Trading Account - 17th July 19
Bitcoin Is Far Too Risky for Most Investors - 17th July 19
Core Inflation Rises but Fed Is Going to Cut Rates. Will Gold Gain? - 17th July 19
Boost your Trading Results - FREE eBook - 17th July 19
This Needs To Happen Before Silver Really Takes Off - 17th July 19
NASDAQ Should Reach 8031 Before Topping - 17th July 19
US Housing Market Real Terms BUY / SELL Indicator - 16th July 19
Could Trump Really Win the 2020 US Presidential Election? - 16th July 19
Gold Stocks Forming Bullish Consolidation - 16th July 19
Will Fed Easing Turn Out Like 1995 or 2007? - 16th July 19
Red Rock Entertainment Investments: Around the world in a day with Supreme Jets - 16th July 19

Market Oracle FREE Newsletter

Top AI Stocks Investing to Profit from the Machine Intelligence Mega-trend

These Promising Cancer Therapies Are a Biotech Stocks "Triple Play"

Companies / BioTech Jun 19, 2015 - 03:04 PM GMT

By: ...

Companies Ernie Tremblay writes: On Jan. 7, 2015, CytRX Corp. (NASDAQ: CYTR) announced positive results from a study of its experimental brain cancer drug, aldoxorubicin, and the company's stock immediately jumped 15.8%. Then, over the next four months, it nearly doubled.

Over the months since June 2013, when Clovis Oncology Inc. (NASDAQ: CLVS) released positive trial data for both a lung cancer and a lymphoma drug, CLVS share value has soared 255%.

And just last summer, when Puma Biotechnology Inc. (NYSE: PBYI) released positive results from a clinical trial of its breast cancer drug, neratanib, PBYI shares jumped 300% in a single session.

It's clear that investors can do very well with the right cancer drug.

But there, of course, is the rub: Finding the right cancer drug is not so easy.

I'm about to show you three companies – all sound investments – running strong in the race to fight this scourge, and the one that could very well take the prize…

Biotech Investing's Biggest Challenge

According to a study published in the September 2013 issue of Clinical Pharmacology and Therapeutics, only 9.8% of all experimental drugs designed to treat solid tumors make it to final FDA approval – fewer than one in 10.

So the odds are not in your favor.

The same study, however, pinpointed one area of cancer research where success isn't so elusive: treatments for blood cancers, such as leukemias and lymphomas. In fact, more than one out of every three (36%) of these compounds will make it to market.

Some companies are making significant strides in the war against these diseases right now.

One approach, called chimeric antigen receptor (CAR) T-cell therapy, represents the cutting edge of current oncology. It involves removing T cells (immune cells produced by the thymus gland) from a cancer patient, genetically altering them so they can detect the individual's specific cancer, and injecting them back into the bloodstream, where they can directly attack the disease. It's a combination of immunotherapy, cell therapy, and gene therapy.

CAR-T has yielded some impressive results.

Researchers at Juno Therapeutics Inc. (NASDAQ: JUNO), for example, announced that in an ongoing phase 1 trial of its CAR-T cell therapy,  JCAR015, 24 of 27 adults with acute lymphoblastic leukemia (ALL), all of whom had ceased responding to other therapies, went into remission. Six of those patients remained disease-free for more than a year. Without CAR-T, most would likely have died within weeks or months.

As a result, Juno had a huge IPO in 2014 and saw its valuation grow from $2 billion to $4.7 billion in the first month. The company plans to test CAR-T cells in clinical trials against six different types of cancer by the end of next year.

Bellicum Pharmaceuticals Inc. (NASDAQ: BLCM), another small biotech developing CAR T-cell therapies, is creating CAR-Ts that not only recognize cancer cells, but also respond to a medical "on-off switch," a drug called rimiducid, which, in the presence of cancer, can awaken the CAR-Ts from a dormant state and send them to work.

If either the drug or cancer cells are absent, the T cells turn off. Having the switch helps control the toxicity of the therapy. The company calls their cells "GoCAR-Ts."

Bellicum's cell therapy for hematologic cancers, BPX-401, is in preclinical development for the treatment of acute ALL, chronic lymphocytic leukemia (CLL), and certain types of non-Hodgkin's lymphoma. The company says, "We have generated preclinical proof-of-principle data in vitro showing that BPX-401 has significant CAR-T cell activation and proliferation potential, and may be more effective in killing cancer cells compared to other CAR-T constructs."

Bellicum's share price currently hovers around $23, with a market cap of $597 million, but those numbers should jump considerably higher as the company's CAR-T compounds move into clinical trials.

The "Fly in the Ointment"

For all of their promise, current CAR-T therapies come with significant downside: They can kill you.

A number of deaths have occurred in CAR-T trial studies, both at JUNO's Labs and at the University of Pennsylvania. The deaths resulted from cytokine syndrome, a release of inflammatory immune substances such as interferon, interleukin, and various growth factors, in response to T-cell activation.

These so-called "cytokine storms" can result in high fever, muscle aches, low blood pressure, delirium, and excess fluid in the lungs.

Both Juno and Bellicum are working on strategies to lower the risk of this kind of toxic response, but whether their strategies will work remains to be seen.

So for all of its promise, CAR-T may represent merely a transitional point to another type of therapy altogether – one that is safer and more effective, and may even prove to be a "magic bullet" for all cancers.

This Is Nothing Less Than the Future of Cancer Therapy

When cells of any sort grow old, sick, or damaged, the immune system creates large hunter/scavenger cells called macrophages that find, engulf, and devour them. The process is called phagocytosis.

Nearby healthy cells avoid this fate because they carry significant amounts of a signal protein, CD47, on their surfaces, which acts like a flashing sign that says, "Do not eat me!"

Unhealthy cells lose much of their ability to express CD47 and also give off other signals that attract hungry macrophages. They quickly become lunch.

But cancer cells, even though they're diseased, have developed the ability to make a lot of CD47 and camouflage themselves with it to avoid certain destruction.

That suggests a new approach to fighting the disease: CD47 blockade. Currently, scientists are developing ways to prevent cancer cells from producing the protein, leaving them with no place to hide.

Much of the research is being done by a group of researchers under the leadership of Irving Weissman, M.D., at Stanford University, where they're working to develop a monoclonal antibody that will unmask cancer cells for hunting macrophages.

Of more interest to investors, however, is the CD47 inhibitor under development at an immuno-oncology development biotech called Trillium Therapeutics Inc. (NASDAQ: TRIL).

Trillium's inhibitor, SIRPαFc, is a fusion protein that binds with CD47 and prevents it from broadcasting its "don't eat me" signal.

The company is currently planning to begin a phase 1 clinical trial in H2 2015 to test the efficacy of SIRPαFc on acute myeloid leukemia (AML). It has already demonstrated that SIRPαFc binds well with AML-expressed CD47 in xenograph models. (A xenograph is a human tumor that has been grafted onto an animal host.)

This approach to fighting blood cancers is extremely promising, but it's not the end of the story. As it turns out, CD47 blockade may be a treatment that works against all cancers – there are more than 200 variations – because all malignant tumors, no matter the type, express CD47 for survival. Until now, researchers have assumed there would never be this kind of "magic bullet."

The science behind this approach is well established, and the possibility of efficacy in humans is promising. The more immediate question, however, concerns safety, because theoretically, CD47 inhibitors could bind with healthy red blood cells, making them targets for phagocytosis.

With SIRPαFc, this turns out not to be the case, as it binds well with cancer cells, but poorly with blood cells. This may give it a safety advantage over the monoclonal antibody approach at Stanford, and also a similar program at Celgene Corp. (NASDAQ: CELG), in partnership with a privately owned biotech called Inhibrx.

The Best Investment Opportunity of Them All

Trillium is a remarkable investment opportunity. For AML alone, assuming an annual treatment cost of around $75,000 per year, averaged worldwide, and a peak market penetration of 23%, sales could top $900 million for this indication alone.

But TRIL isn't stopping with AML. It's also looking into indications for other blood cancers and solid tumors as well.

If CD47 blockade works as well as the science predicts it should, TRIL's earning potential will be unlimited.

All in all, Juno and Bellicum remain sound investment opportunities for now, but in the long run, Trillium may well win the race.

More from Ernie

They call it the "Boomer Virus" and it kills every 58 seconds. A highly contagious virus is sweeping the globe and has made its way to the United States. It's 1,000 times more deadly than Ebola and kills every 58 seconds. Millions of Americans are already infected and don't even know it… and Boomers are five times more likely to contract this infection. Fortunately, a tiny $7 company is providing a patented medical breakthrough that could save 75 million Americans from a grisly death. Do not ignore this warning. It's a matter of life and death. Continue reading here

Source :

Money Morning/The Money Map Report

©2015 Monument Street Publishing. All Rights Reserved. Protected by copyright laws of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), of content from this website, in whole or in part, is strictly prohibited without the express written permission of Monument Street Publishing. 105 West Monument Street, Baltimore MD 21201, Email:

Disclaimer: Nothing published by Money Morning should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investent advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication, or after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended by Money Morning should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

© 2005-2019 - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.

Post Comment

Only logged in users are allowed to post comments. Register/ Log in

6 Critical Money Making Rules